However, RAS/MAPK pathway activity is linked to breast cancer progress43,44 and maybe dysregulated by overexpression of upstream receptor tyrosine kinases such as human epidermal growth factor receptors 1 and 2 (aka HER1 and HER2), as commonly observed in breast cancer.45 Here, ERBB2 is linked to breast carcinoma.